Datapoint: AbbVie’s Rinvoq Chalks Up Atopic Dermatitis Win

The FDA on Jan. 14 approved AbbVie’s Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 and older who have not responded to previous treatments. The JAK inhibitor was approved for daily use in both its 15mg and 30mg strengths, which could give it a competitive edge. For the treatment of rheumatoid arthritis, Rinvoq currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. 37% of covered lives have preferred access to Rinvoq.

SOURCE: MMIT Analytics, as of 1/19/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today